Methylprednisolone acetate
- CA: ℞-only / OTC
- [2-[(6S,10R,11S,13S,17R)-11,17-Dihydroxy-6,10,13-trimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl] acetate
- 53-36-1
- 45357932
- DBSALT001157
- 5666
- 43502P7F0P
- D00979
- CHEBI:6889
- ChEMBL1364144
- DTXSID7023302
![Edit this at Wikidata](http://upload.wikimedia.org/wikipedia/en/thumb/8/8a/OOjs_UI_icon_edit-ltr-progressive.svg/10px-OOjs_UI_icon_edit-ltr-progressive.svg.png)
- Interactive image
- C[C@H]1CC2C3CC[C@@]([C@]3(C[C@@H](C2[C@@]4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)C)O
- InChI=1S/C24H32O6/c1-13-9-16-17-6-8-24(29,20(28)12-30-14(2)25)23(17,4)11-19(27)21(16)22(3)7-5-15(26)10-18(13)22/h5,7,10,13,16-17,19,21,27,29H,6,8-9,11-12H2,1-4H3/t13-,16?,17?,19-,21?,22-,23-,24-/m0/s1
- Key:PLBHSZGDDKCEHR-UFBGDBPHSA-N
Methylprednisolone acetate, sold under the brand names Depo-Medrol among others, is a synthetic glucocorticoid corticosteroid and a corticosteroid ester—specifically the C21 acetate ester of methylprednisolone—which is used in clinical and veterinary medicine.[1][2][3][4][5][6][7] It has been formulated as an aqueous suspension for intramuscular, intra-articular, soft tissue, and intralesional injection alone and in combination with lidocaine, a local anesthetic.[1][4][5] Methylprednisolone acetate was previously suspended with polyethylene glycol but is no longer formulated with this excipient due to concerns about possible toxicity.[6][8] Depo methylprednisolone acetate is a depot injection and is absorbed slowly with a duration of weeks to months with a single intramuscular injection.[5]
See also
References
- ^ a b "Depo-Medrol- methylprednisolone acetate injection, suspension". DailyMed. 18 January 2019. Retrieved 19 February 2020.
- ^ Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 811–. ISBN 978-1-4757-2085-3.
- ^ Index Nominum 2000: International Drug Directory. Taylor & Francis. 2000. pp. 675–. ISBN 978-3-88763-075-1.
- ^ a b Muller NF, Dessing RP, eds. (19 June 1998). European Drug Index: European Drug Registrations (Fourth ed.). CRC Press. pp. 337–. ISBN 978-3-7692-2114-5.
- ^ a b c Plumb DC (21 February 2018). Plumb's Veterinary Drug Handbook: Pocket. John Wiley & Sons. pp. 1088–1091. ISBN 978-1-119-34649-4.
- ^ a b Lennard TA, Vivian DG, Walkowski, Singla AK (11 June 2011). Pain Procedures in Clinical Practice E-Book. Elsevier Health Sciences. pp. 8–. ISBN 978-1-4377-3774-5.
- ^ Scott DW, Miller Jr WH (1 December 2010). Equine Dermatology - E-Book. Elsevier Health Sciences. pp. 122–. ISBN 978-1-4377-0921-6.
- ^ Canale ST, Beaty JH (29 October 2012). Campbell's Operative Orthopaedics E-Book. Elsevier Health Sciences. pp. 1906–. ISBN 978-0-323-08718-6.
- v
- t
- e
- Antagonists: Aglepristone
- Ketoconazole
- Mifepristone
- Ulipristal acetate
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
- See also
- Glucocorticoid receptor modulators
- Mineralocorticoids and antimineralocorticoids
- List of corticosteroids
![]() | This article about a steroid is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e